XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

- XPOVIO^® is the first and only approved XPO1 inhibitor in Indonesia.

- From the second half of 2024 to now, XPOVIO^® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO^® has been approved for multiple indications in ten markets across the APAC region.

Read more at prnewswire.com